For the quarter ended March 2026, Travere Therapeutics (TVTX) reported revenue of $127.2 million, up 55.6% over the same period last year. EPS came in at -$0.39, compared to -$0.47 in the year-ago quarter.
The reported revenue represents a surprise of -1.84% over the Zacks Consensus Estimate of $129.58 million. With the consensus EPS estimate being -$0.30, the EPS surprise was -30.74%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Travere performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
-
Revenue- Tiopronin products: $19.34 million versus the six-analyst average estimate of $20.4 million. The reported number represents a year-over-year change of -3.2%.
-
Revenue- Total net product sales: $124.49 million compared to the $124.88 million average estimate based on six analysts. The reported number represents a change of +64.1% year over year.
-
Revenue- FILSPARI: $105.15 million compared to the $104.48 million average estimate based on six analysts. The reported number represents a change of +88.2% year over year.
-
Revenue- License and collaboration revenue: $2.71 million compared to the $4.68 million average estimate based on six analysts. The reported number represents a change of -53.9% year over year.
View all Key Company Metrics for Travere here>>>
Shares of Travere have returned +44.9% over the past month versus the Zacks S&P 500 composite's +10% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Travere Therapeutics, Inc. (TVTX) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
